Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin
R Otsubo, T Yasui - Pharmacology & Therapeutics, 2022 - Elsevier
Antibody therapy is effective for treating infectious diseases. Due to the coronavirus disease
2019 (COVID-19) pandemic and the rise of drug-resistant bacteria, rapid development of …
2019 (COVID-19) pandemic and the rise of drug-resistant bacteria, rapid development of …
Antibodies and vaccines against botulinum toxins: available measures and novel approaches
C Rasetti-Escargueil, MR Popoff - Toxins, 2019 - mdpi.com
Botulinum neurotoxin (BoNT) is produced by the anaerobic, Gram-positive bacterium
Clostridium botulinum. As one of the most poisonous toxins known and a potential …
Clostridium botulinum. As one of the most poisonous toxins known and a potential …
Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B
Y Jiang, R Wang, J Guo, K Cheng, L Chen… - Frontiers in …, 2024 - frontiersin.org
Background Botulinum neurotoxin (BoNT) produced by Clostridium botulinum is one of the
most potent known toxins. Moreover, BoNT is classified as one of the most important …
most potent known toxins. Moreover, BoNT is classified as one of the most important …
Challenges in searching for therapeutics against Botulinum Neurotoxins
M Pirazzini, O Rossetto - Expert opinion on drug discovery, 2017 - Taylor & Francis
ABSTRACT Introduction: Botulinum neurotoxins (BoNTs) are the most potent toxins known.
BoNTs are responsible for botulism, a deadly neuroparalytic syndrome caused by the …
BoNTs are responsible for botulism, a deadly neuroparalytic syndrome caused by the …
A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype E subtypes
Human botulism is most commonly caused by botulinum neurotoxin (BoNT) serotypes A, B,
and E. For this work, we sought to develop a human monoclonal antibody (mAb)-based …
and E. For this work, we sought to develop a human monoclonal antibody (mAb)-based …
A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes
Y Fan, C Garcia-Rodriguez, J Lou, W Wen, F Conrad… - PloS one, 2017 - journals.plos.org
Human botulism is primarily caused by botulinum neurotoxin (BoNT) serotypes A, B and E,
with around 1% caused by serotype F (BoNT/F). BoNT/F comprises at least seven different …
with around 1% caused by serotype F (BoNT/F). BoNT/F comprises at least seven different …
Evaluation of anti-botulinum neurotoxin single domain antibodies with additional optimization for improved production and stability
LC Shriver-Lake, D Zabetakis, ER Goldman… - Toxicon, 2017 - Elsevier
Botulinum neurotoxin (BoNT) is a highly potent and lethal toxin, which even in minute
quantities can lead to death. BoNT occurs in seven well described serotypes, AG, and it is …
quantities can lead to death. BoNT occurs in seven well described serotypes, AG, and it is …
Safety and pharmacokinetics of a four monoclonal antibody combination against botulinum C and D neurotoxins
DM Snow, K Riling, A Kimbler, Y Espinoza… - Antimicrobial agents …, 2019 - Am Soc Microbiol
Botulism is caused by botulinum neurotoxin (BoNT), the most poisonous substance known.
BoNTs are also classified as tier 1 biothreat agents due to their high potency and lethality …
BoNTs are also classified as tier 1 biothreat agents due to their high potency and lethality …
A Three-Monoclonal Antibody Combination Potently Neutralizes BoNT/G Toxin in Mice
Equine-derived antitoxin (BAT®) is the only treatment for botulism from botulinum neurotoxin
serotype G (BoNT/G). BAT® is a foreign protein with potentially severe adverse effects and is …
serotype G (BoNT/G). BAT® is a foreign protein with potentially severe adverse effects and is …
A monoclonal antibody combination against both serotypes A and B botulinum toxin prevents inhalational botulism in a guinea pig model
DM Snow, RR Cobb, J Martinez, I Finger-Baker… - Toxins, 2021 - mdpi.com
Botulinum neurotoxins (BoNT) are extremely potent and can induce respiratory failure,
requiring long-term intensive care to prevent death. Recombinant monoclonal antibodies …
requiring long-term intensive care to prevent death. Recombinant monoclonal antibodies …